share_log

Truist Securities Reiterates Buy on Immunovant, Maintains $48 Price Target

Moomoo 24/7 ·  Mar 25 12:11

Truist Securities analyst Robyn Karnauskas reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $48 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment